Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17765411 | 0.88 | MAPT (0.42) | DHFRCYP1A2FFAR1KDM4EMEN1 | |
| SCHEMBL17765393 | 0.85 | APP (0.41) | ACACBSLC16A3DHFRCYP1A2FFAR1 | |
| SCHEMBL17765427 | 0.85 | APP (0.41) | ACACBSLC16A3DHFRCYP1A2FFAR1 | |
| SCHEMBL17773363 | 0.83 | MAPT (0.41) | DHFRCYP1A2FFAR1KDM4EMEN1 | |
| SCHEMBL17765410 | 0.83 | FFAR1 (0.41) | ACACBFFAR1 | |
| SCHEMBL17765433 | 0.83 | NPC1 (0.36) | CYP1A2FFAR1KDM4EMEN1NPC1 | |
| SCHEMBL17765455 | 0.83 | TSHR (0.39) | CYP1A2FFAR1KDM4EMEN1NPC1 | |
| SCHEMBL17777988 | 0.81 | MAPT (0.41) | DHFRCYP1A2FFAR1KDM4EMEN1 | |
| SCHEMBL17765414 | 0.80 | PTGES (0.36) | ACACBCYP1A2FFAR1KDM4EMEN1 | |
| SCHEMBL17765422 | 0.80 | PTGES (0.36) | ACACBCYP1A2FFAR1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676679-B2 | Traceless directing groups in radical cascades: from oligoalkynes to fused helicenes without tethered initators | The Florida State University Research Foundation, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676679-B2 | Traceless directing groups in radical cascades: from oligoalkynes to fused helicenes without tethered initators | The Florida State University Research Foundation, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160145276-A1 | TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS | The Florida State University Research Foundation, Inc | 2016-05-26 | — | — | US | disclosed |
| US-20160145276-A1 | TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS | The Florida State University Research Foundation, Inc | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145276-A1 | TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS | OR51E2, OR10J3, ORC3 | ASIC3 1607/4885ACACB 2924/4885PDGFRB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.